New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0

BackgroundWe recently developed a freely available mobile app (TB Mobile) for both iOS and Android platforms that displays Mycobacterium tuberculosis (Mtb) active molecule structures and their targets with links to associated data. The app was developed to make target information available to as large an audience as possible.ResultsWe now report a major update of the iOS version of the app. This includes enhancements that use an implementation of ECFP_6 fingerprints that we have made open source. Using these fingerprints, the user can propose compounds with possible anti-TB activity, and view the compounds within a cluster landscape. Proposed compounds can also be compared to existing target data, using a näive Bayesian scoring system to rank probable targets. We have curated an additional 60 new compounds and their targets for Mtb and added these to the original set of 745 compounds. We have also curated 20 further compounds (many without targets in TB Mobile) to evaluate this version of the app with 805 compounds and associated targets.ConclusionsTB Mobile can now manage a small collection of compounds that can be imported from external sources, or exported by various means such as email or app-to-app inter-process communication. This means that TB Mobile can be used as a node within a growing ecosystem of mobile apps for cheminformatics. It can also cluster compounds and use internal algorithms to help identify potential targets based on molecular similarity. TB Mobile represents a valuable dataset, data-visualization aid and target prediction tool.

[1]  Lynn Rasmussen,et al.  High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. , 2012, Tuberculosis.

[2]  Thomas Dick,et al.  In silico analyses for the discovery of tuberculosis drug targets. , 2013, The Journal of antimicrobial chemotherapy.

[3]  Sean Ekins,et al.  Combining Cheminformatics Methods and Pathway Analysis to Identify Molecules with Whole-Cell Activity Against Mycobacterium Tuberculosis , 2012, Pharmaceutical Research.

[4]  Sean Ekins,et al.  Fusing Dual-Event Data Sets for Mycobacterium tuberculosis Machine Learning Models and Their Evaluation , 2013, J. Chem. Inf. Model..

[5]  David Beer,et al.  A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating Mycobacterium tuberculosis , 2012, ACS chemical biology.

[6]  Lynn Rasmussen,et al.  Antituberculosis activity of the molecular libraries screening center network library. , 2009, Tuberculosis.

[7]  Sean Ekins,et al.  Validating New Tuberculosis Computational Models with Public Whole Cell Screening Aerobic Activity Datasets , 2011, Pharmaceutical Research.

[8]  Srinivasa P. S. Rao,et al.  Structural Basis of Mycobacterial Inhibition by Cyclomarin A , 2013, The Journal of Biological Chemistry.

[9]  Philip E. Bourne,et al.  The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications , 2010, PLoS Comput. Biol..

[10]  Sean Ekins,et al.  A collaborative database and computational models for tuberculosis drug discovery. , 2010, Molecular bioSystems.

[11]  Egon L. Willighagen,et al.  CDK-Taverna: an open workflow environment for cheminformatics , 2010, BMC Bioinformatics.

[12]  Andreas Bender,et al.  Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. , 2009, Journal of proteome research.

[13]  Stefan Niemann,et al.  Drug resistance-conferring mutations in Mycobacterium tuberculosis from Madang, Papua New Guinea , 2012, BMC Microbiology.

[14]  Giovanni B Migliori,et al.  The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? , 2012, The Lancet.

[15]  Damiano Banfi,et al.  Leads for antitubercular compounds from kinase inhibitor library screens. , 2010, Tuberculosis.

[16]  Rebecca Voelker,et al.  MDR-TB has new drug foe after fast-track approval. , 2013, JAMA.

[17]  C. Steinbeck,et al.  Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics. , 2006, Current pharmaceutical design.

[18]  Carlos Simmerling,et al.  CoA Adducts of 4-Oxo-4-Phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis Menaquinone Biosynthesis Pathway. , 2011, ACS medicinal chemistry letters.

[19]  David Rogers,et al.  Cheminformatics analysis and learning in a data pipelining environment , 2006, Molecular Diversity.

[20]  Ekins Sean,et al.  Using TB Mobile to Predict Potential Targets for TB hits from Phenotypic Screening , 2013 .

[21]  Antony J. Williams,et al.  Cheminformatics workflows using mobile apps , 2013 .

[22]  A. Golas,et al.  Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. , 2013, ACS chemical biology.

[23]  Kalidas Yeturu,et al.  targetTB: A target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis , 2008, BMC Systems Biology.

[24]  Marc A. Martí-Renom,et al.  Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis , 2013, PLoS Comput. Biol..

[25]  G. Kearns,et al.  Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[26]  Vijay T. Ahuja,et al.  Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy. , 2014, Bioorganic & medicinal chemistry letters.

[27]  Sean Ekins,et al.  Open Drug Discovery Teams: A Chemistry Mobile App for Collaboration , 2012, Molecular informatics.

[28]  Stanislas Leibler,et al.  Sumit Chakraborty Mycobacterium tuberculosis Metabolism in-Aminosalicylic Acid Acts as an Alternative Substrate of Folate Para , 2014 .

[29]  Noriaki Iwase,et al.  Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. , 2012, ACS chemical biology.

[30]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[31]  A. Saxena,et al.  Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase. , 2013, International journal of antimicrobial agents.

[32]  Alex M. Clark,et al.  TB Mobile: a mobile app for anti-tuberculosis molecules with known targets , 2013, Journal of Cheminformatics.

[33]  Sean Ekins,et al.  Enhancing Hit Identification in Mycobacterium tuberculosis Drug Discovery Using Validated Dual-Event Bayesian Models , 2013, PloS one.

[34]  Alex M. Clark,et al.  Basic primitives for molecular diagram sketching , 2010, J. Cheminformatics.

[35]  L. Gabbasova,et al.  Global tuberculosis report (2014) , 2014 .

[36]  Xueqin Hao,et al.  Identification and validation of a novel lead compound targeting 4-diphosphocytidyl-2-C-methylerythritol synthetase (IspD) of mycobacteria. , 2012, European journal of pharmacology.

[37]  S Brindha,et al.  Informatics resources for tuberculosis--towards drug discovery. , 2012, Tuberculosis.

[38]  Pedro M Alzari,et al.  Rising standards for tuberculosis drug development. , 2008, Trends in pharmacological sciences.

[39]  Zhen Liu,et al.  Discovery of Novel Acetohydroxyacid Synthase Inhibitors as Active Agents against Mycobacterium tuberculosis by Virtual Screening and Bioassay , 2013, J. Chem. Inf. Model..

[40]  C. Ball,et al.  TB database 2010: overview and update. , 2010, Tuberculosis.

[41]  Alfonso Mendoza,et al.  Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis , 2013, ChemMedChem.

[42]  Sharmila Anishetty,et al.  Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis , 2005, Comput. Biol. Chem..

[43]  Lynn Rasmussen,et al.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.

[44]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[45]  D. Rogers,et al.  Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.

[46]  Joel S. Freundlich,et al.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. , 2011, Trends in Microbiology.

[47]  Osmar Norberto de Souza,et al.  Discovery of New Inhibitors of Mycobacterium tuberculosis InhA Enzyme Using Virtual Screening and a 3D-Pharmacophore-Based Approach , 2013, J. Chem. Inf. Model..

[48]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[49]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[50]  Egon L. Willighagen,et al.  The Chemistry Development Kit (CDK): An Open-Source Java Library for Chemo-and Bioinformatics , 2003, J. Chem. Inf. Comput. Sci..

[51]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[52]  Alimuddin Zumla,et al.  WHO's 2013 global report on tuberculosis: successes, threats, and opportunities , 2013, The Lancet.

[53]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[54]  George Karypis,et al.  Target Fishing for Chemical Compounds Using Target-Ligand Activity Data and Ranking Based Methods , 2009, J. Chem. Inf. Model..

[55]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[56]  Sean Ekins,et al.  Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery , 2013, Pharmaceutical Research.

[57]  Takushi Kaneko,et al.  Challenges and opportunities in developing novel drugs for TB. , 2011, Future medicinal chemistry.

[58]  Sean Ekins,et al.  Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. , 2010, Molecular bioSystems.

[59]  Alex M. Clark,et al.  Accurate Specification of Molecular Structures: The Case for Zero-Order Bonds and Explicit Hydrogen Counting , 2011, J. Chem. Inf. Model..

[60]  R. Reynolds,et al.  High Throughput Screening for Inhibitors of Mycobacterium tuberculosis H 37 Rv , 2012 .

[61]  Sean Ekins,et al.  Redefining Cheminformatics with Intuitive Collaborative Mobile Apps , 2012, Molecular informatics.

[62]  D. Sherman,et al.  Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis , 2013, PloS one.

[63]  Barry A. Bunin,et al.  Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. , 2013, Chemistry & biology.

[64]  Sean Ekins,et al.  Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. , 2009, Drug discovery today.

[65]  P Willett,et al.  Similarity-based approaches to virtual screening. , 2003, Biochemical Society transactions.

[66]  Larry Ross,et al.  A novel quinoline derivative that inhibits mycobacterial FtsZ. , 2013, Tuberculosis.

[67]  Sean Ekins,et al.  Mobile apps for chemistry in the world of drug discovery. , 2011, Drug discovery today.

[68]  Anup D. Shah,et al.  Crowd Sourcing a New Paradigm for Interactome Driven Drug Target Identification in Mycobacterium tuberculosis , 2012, PloS one.

[69]  Alex M. Clark,et al.  Incorporating Green Chemistry Concepts into Mobile Chemistry Applications and Their Potential Uses , 2013 .

[70]  Christian Stolte,et al.  TB database: an integrated platform for tuberculosis research , 2008, Nucleic Acids Res..

[71]  Sean Ekins,et al.  Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis. , 2014, Tuberculosis.